Navigation Links
Astellas Seeks Rigorous Testing and Safety-Related Labeling for Anti-Rejection Medications
Date:8/10/2009

DEERFIELD, Ill., Aug. 10 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") announced today that the U.S. Food and Drug Administration (FDA) has substantially denied the company's Citizen Petition to ensure the safe and effective use of immunosuppressants (also called anti-rejection medications) used to prevent rejection in organ transplant patients. In their petition, Astellas requested that the FDA take additional measures to protect transplant recipients, a unique and vulnerable patient population, from substitute critical dose immunosuppressant drugs that have not demonstrated bioequivalence in rigorous clinical trials in transplant patients.

In response, Astellas plans to file a complaint for declaratory and injunctive relief in U.S. District Court in Washington, D.C. challenging the FDA's decision to apply standard bioequivalence testing for the approval of generic immunosuppressant drugs, like tacrolimus. These critical dose drugs have a narrow therapeutic margin for safety and efficacy. Under the FDA's decision, bioequivalence testing is required only in healthy volunteers, not the patient population that will be treated with the new product. Bioequivalence testing measures how closely the absorption of the active ingredient in a generic drug mirrors that of an innovator drug. A generic drug must demonstrate that it falls within an acceptable range of absorption, as compared to the innovator drug. Absorption, and the clinical effect of these critical dose drugs, is affected by a number of factors, including interactions with other medications, and concurrent medical conditions. Transplant patients are at high risk for organ rejection and are often dealing with a host of medical issues, as well as taking an average of ten medications.

Additionally, the FDA denied Astellas' request for labeling changes that require physicians to be notified whenever a substituted oral
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Cardiome And Astellas Announce Regulatory Update
2. FDA Approves Additional Indication for Astellas MYCAMINE(R)
3. Astellas/GlaxoSmithKlines Vesicare Has Advantages Over Pfizers Detrol LA/Detrusitol XL in Reducing Episodes of Urge Urinary Incontinence
4. Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
5. Astellas Announces New Vice President of Marketing
6. Astellas Hires New Vice President of Compliance
7. Astellas Adds CNS Therapy Area Leader to Global R&D Team
8. Astellas Names Head of Global R&D Operations
9. NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM)
10. AUA Foundation names the 2009 Astellas Rising Stars in Urology award winners
11. Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Park Cities Pet Sitter , Inc. has announced ... donation drive that benefits the animal shelter and rescue communities. ... with the Humane Society of the United States’ Animal Shelter ... , As part of their participation, Park Cities Pet Sitter ... the Presents 4 Pets drive from their client base, as ...
(Date:8/20/2014)... PITTSBURGH, Aug. 20, 2014 A common approach to ... blood did not improve survival chances for people who ... experts at the University of Pittsburgh School of Medicine. ... PLOS One , suggest acute hemodialysis, an aggressive method ... failure, may not provide a definitive benefit to the ...
(Date:8/20/2014)... With 3943.8% growth, Connexion Point ranks number ... fastest growing companies. The Inc. 500 ranks Connexion Point 12th, ... Point is the #1 fastest growing company in Utah. , ... and its clients include four of the top 10 health ... and has offices and contact centers in Salt Lake City, ...
(Date:8/20/2014)... cancer - using Botox. A study presented in the ... shows that cancer growth could be suppressed by eliminating ... cancer stem cells. The approach thus treated the cancer. ... and efficient. The researchers have thus far tested the ... humans. , The nervous system is crucial in regulating ...
(Date:8/20/2014)... most common cause of endophthalmitis, a potentially blinding condition ... eye injections, are the well-known staphylococci ("staph") ... a study published in the August issue of ... years of cases at New York Eye and Ear ... study found that gram-positive bacteria, which include staph and ...
Breaking Medicine News(10 mins):Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 2Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 3Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 4Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:With 3943.8% Growth, Connexion Point, a Leader in Contact Centers for Health Care, Ranks 86th on the Inc. 500 List as One of the Nation’s Fastest Growing Companies 2Health News:Treating gastric cancer -- with Botox 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 3
... Pills Can Make Headaches Worse, YONKERS, N.Y., ... from frequent headaches to talk to their doctors,before ... prescription,and over-the-counter pain medications can make headaches worse, ... who reports in,CR,s October issue on how some ...
... Resources and Helpline Now,Available, HARRISBURG, Pa., Sept. 2 ... Indoor Air Act fast approaching, the,Department of Health is ... the law that will ban smoking in most public ... Guidance and a downloadable toolkit for public places ...
... new presidential,administration on the way, health care reform ... on what may come, attendees of the 2008,Republican ... than,Halleland Health Consulting, which is making itself available ... group and its law firm parent -- Minneapolis-based,Halleland ...
... Inc.,(NYSE: CSA ) announces the signing of ... office building and outpatient treatment center in,Pensacola, Florida., ... first synergy project since the,closing of the merger ... Spencer Company). The project will include design/build,(architectural, engineering ...
... Californians took benefit of nation,s 1st such law, passed in ... with chronically ill kids have made use of California,s pioneering ... even aware it exists, according to researchers at the Rand ... family leave law. It is funded by employees through an ...
... Pollution, HARRISBURG, Pa., Sept. 2 The ... partnerships have,forecast an air quality action day for ... air quality forecast predicts Wednesday will be code ... Washington and,Westmoreland counties., The U.S. Environmental Protection ...
Cached Medicine News:Health News:Consumer Reports Urges Chronic Headache Sufferers to Examine Their Use of Pain Relief Drugs 2Health News:Consumer Reports Urges Chronic Headache Sufferers to Examine Their Use of Pain Relief Drugs 3Health News:PA Department of Health Reminds Businesses to Prepare to Implement Clean Indoor Air Act 2Health News:INTERVIEW AVAILABILITY: Halleland Health Consulting Makes Health Policy Expertise Available During RNC Week 2Health News:Cogdell Spencer Announces First Synergy Project in Pensacola, Florida 2Health News:Cogdell Spencer Announces First Synergy Project in Pensacola, Florida 3Health News:Paid Family Leave Program Goes Mostly Unused 2Health News:Air Quality Action Day Forecast Wednesday for Pittsburgh Region 2
(Date:8/20/2014)... Trovagene, Inc. (NASDAQ:   TROV), a developer ... two clinical studies will be presented at the 29th ... test for the detection of high risk strains of ... take place in Seattle from ... a new U.S. patent was issued earlier this year ...
(Date:8/20/2014)... , August 20, 2014 ... Conducted in the US  KalVista Pharmaceuticals ("KalVista"), ... edema (DME), today announces that it has begun a ... plasma kallikrein inhibitor, KVD001, for the treatment of DME. ... of the Beetham Eye Institute, Joslin Diabetes Center; Harvard ...
(Date:8/19/2014)... , Aug. 19, 2014 Minimally Invasive Devices ... medical device company, announced today that Mitsubishi Corporation has ... robotic visualization system in Japan . ... in Japan in the second ... the exclusive distributor for Karl Storz GMBH & Co. ...
Breaking Medicine Technology:Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2